[Current concept of the management of rheumatoid arthritis based on the pathogenesis].
A new therapeutic concept for the management of rheumatoid arthritis (RA) is strongly required since most traditional methods have failed to introduce remission. This paper attempted to review over novel therapeutic approaches based on the advanced program especially on early stage of RA. Clinical improvement has been observed with tripple combined therapy using such as bucillamine, methotraxate, and sufphasulzopyridine. However, more basic therapeutic program would be required based on the pathogenesis of RA. Here the future development of therapeutic approach including targetting immunosuppression or gene targetting on proliferated synovium has been discussed.
Nishioka
K
K
Rheumatology Division, St. Marianna University.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000209:etiology / Q000628:therapy*; D001379:Azathioprine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015316:Genetic Therapy; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012192:Retroviridae Infections / Q000150:complications; D013583:Synovial Membrane / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003520:Cyclophosphamide; D011239:Prednisolone; D001379:Azathioprine; D008727:Methotrexate